Drug Discovery

Peregrine Pharmaceuticals cuts 20% of workforce to reduce costs

Peregrine Pharmaceuticals has cut down its workforce by up to 20%, as part of its efforts to decrease costs and achieve overall profitability.

Tissue Regenix acquires CellRight Technologies

UK-based regenerative medical company Tissue Regenix Group has completed the acquisition of CellRight Technologies, a US-based specialist in regenerative osteoinductive bone scaffolds.

Takeda, Cardurion Pharmaceuticals form cardiovascular development partnership

Takeda Pharmaceutical and Cardurion Pharmaceuticals have created a new cardiovascular development partnership.

Researchers develop new drug that could treat and limit Parkinson’s disease

Binghamton University researchers have developed a new drug that could possibly limit the progression of Parkinson’s disease and also provide better symptom relief.

Bristol-Myers Squibb to acquire IFM Therapeutics to expand cancer pipeline

Bristol-Myers Squibb has agreed to acquire Boston-based IFM Therapeutics for an upfront payment of $300m to strengthen its oncology pipeline.

VenatoRx secures $9.4m to develop new class of antibiotic fro multi-drug resistant bacteria

VenatoRx Pharmaceuticals, which focuses on discovery and development of novel therapies for highly drug resistant bacterial infections, has been awarded up to $9.4m from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator).

VenatoRx Pharmaceuticals raises $42m in new funding round

VenatoRx Pharmaceuticals has raised $42m in a Series B funding round led by Versant Ventures and joined by Abingworth and Foresite Capital.

Lilly and Nektar to jointly develop and commercialize autoimmune therapy

Eli Lilly and Company and Nektar Therapeutics have agreed to jointly develop NKTR-358, a novel immunological therapy discovered by the latter.

Study says machine learning algorithms can help predict schizophrenia

A new study has found that artificial intelligence (AI) and machine learning algorithms helped predict instances of schizophrenia with 74% accuracy.